688301.SH
奕瑞科技
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 97.15
−3.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.3B | 1.8B | 1.9B | 1.5B |
| Cost of Revenue | 1.2B | 1.1B | 913.7M | 802.6M | 660.9M |
| Gross Profit | 1.2B | 1.2B | 917.7M | 1.1B | 888.2M |
| Operating Expenses | |||||
| R&D Expense | 367.7M | 339.7M | 310.2M | 262.7M | 238.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 136.5M | 126.5M | 138.4M | 101.8M | 90.7M |
| Selling & Marketing Expense | 88.0M | 87.2M | 69.7M | 80.2M | 86.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 670.5M | 592.8M | 524.7M | 432.1M | 364.0M |
| Cost and Expenses | 1.9B | 1.7B | 1.4B | 1.2B | 1.0B |
| Operating Income (EBIT) | 721.3M | 683.3M | 507.2M | 683.6M | 708.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 723.4M | 685.7M | 507.3M | 685.0M | 708.7M |
| Income Tax Expense | 44.4M | 53.5M | 56.9M | 80.2M | 70.0M |
| Bottom Line | |||||
| Net Income | 685.7M | 650.0M | 465.2M | 607.5M | 641.3M |
| Earnings from Cont. Ops | 679.0M | 632.2M | 450.4M | 604.8M | 638.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 685.7M | 650.0M | 465.2M | 607.5M | 641.3M |
| Per Share | |||||
| Basic EPS | CN¥3.36 | CN¥3.20 | CN¥2.33 | CN¥4.26 | CN¥6.31 |
| Diluted EPS | CN¥3.36 | CN¥3.09 | CN¥2.28 | CN¥4.18 | CN¥6.30 |
| Revenue Per Share | CN¥11.54 | CN¥11.08 | CN¥9.17 | CN¥13.07 | CN¥15.24 |
| Shares | |||||
| Basic Shares Outstanding | 212.8M | 203.1M | 199.6M | 142.6M | 101.6M |
| Diluted Shares Outstanding | 212.8M | 203.1M | 199.6M | 142.6M | 101.6M |
| Profitability Metrics | |||||
| EBITDA | — | 870.5M | 576.2M | 732.7M | 739.9M |
| D&A | — | 187.1M | 69.0M | 49.1M | 31.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026